Skip to main content

Table 1 Characteristics of included studies in the meta-analysis (MSCs group)

From: Mesenchymal stromal cells as prophylaxis for graft-versus-host disease in haplo-identical hematopoietic stem cell transplantation recipients with severe aplastic anemia?—a systematic review and meta-analysis

Author, reference (publication year)

Study design

Recruitment period

Number of patients

Median age

Sex (M/F)

Type

Conditioning regimen

GVHD prophylaxis

Interval from diagnosis to treatment (M)

Neutrophil recovery (d)

Platelet engraftment

MSCs originals

NOS score

Wang Z-K [31] (2019)

Single-arm study

January 2014-December 2016

35

11.5 (3–18)

18/17

SAA/VSAA (19/16)

Busulfan (Bu) + cyclophosphamide (Cy) + antithymocyte globulin (ATG)

CsA + MMF + MTX

NA

14 (10–22)

18 (9–36)

BM

6

Yue C [32] (2018)

Cases

January 2014-January 2017 

6

23 (15–31)

3/3

VSAA (6)

Busulfan (Bu) + cyclophosphamide (Cy) + antithymocyte globulin (rATG)

CsA + MMF + MTX

2 (1–3.5)

13 (9–19)

15.5 (10–23)

BM

5

Liu Z [33] (2017)

Single-arm study

March 2013-August 2015

44

24 (8–47)

29/15

SAA/VSAA (31/13)

Busulfan (Bu) + cyclophosphamide (Cy) + antithymocyte globulin (ATG)

CsA + MMF + MTX

31.2 (1–249)

12 (8–21)

19 (8–154)

BM

6

Xu L [34] (2018)

Single-arm study

June 2010-August 2013

24

16.5 (5–55)

14/10

SAA (24)

Cyclophosphamide (Cy) + antithymocyte globulin (rATG) + FLU or

CsA + ATG+ CD25Ab + mycophenolate material

NA

11 (10–25)

13 (10–25)

UC

6

Wu Y [35] (2017)

Single-arm study

January 2011-June 2016

77

9 (1–46)

39/38

SAAVSAA/SAA and PNH (72/5)

Cyclophosphamide (Cy) + antithymocyte globulin (ATG) + FLU ± busulfan

CsA + MMF + MTX + CD25Ab

7 (2–182)

12(8–21)

14 (9–30)

UC

5

Li XH [36] (2014)

Single-arm study

October 2006-October 2012

17

19 (4–29)

10/7

SAA/VSAA (8/9)

Cyclophosphamide (Cy) + antithymocyte globulin (ATG) + FLU

CsA + MMF + CD25Ab

3 (1–5)

12 (11–21)

14 (11–75)

UC

6

Wu Y [37] (2014)

Single-arm study

January 2007-June 2013

21

18 (4–31)

11/10

SAA/VSAA/SAA and PNH (7/12/2)

Cyclophosphamide (Cy) + antithymocyte globulin (rATG) + FLU or

CsA + MMF + CD25Ab + rATG

6 (1–128)

12 (8–21)

14(10–23)

UC

6

Wang Z [38] (2014)

Single-arm study

March 2010-April 2013

17

10 (4–19)

6/11

SAA/VSAA/2 HSCT (11/5/1)

BU + fludarabine + CY + ATG

CsA + MMF + MTX + CD25Ab

12 (1–44)

16 (9–25)

22 (9–95)

UC

6

  1. Abbreviations: SAA severe aplastic anemia, VSAA very severe aplastic anemia, ATG antithymoglobulin, CsA cyclosporin A, MSCs mesenchymal stem cells, haplo-HSCT haplo-identical hematopoietic stem cell transplantation, BU busulfan, Cy cyclophosphamide, MMF mycophenolate mofetil, FLU fludarabine, MTX methotrexate, GVHD graft-versus-host disease